Enrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline data expected in 2H2026 Attack dataset continues to accumulate in RAPIDe-3, a pivotal ...

GAAP revenue was $11.4 million for the first quarter of 2025, compared to $11.6 million for the first quarter of 2024. Net loss was $2.0 million for the first quarter of 2025 or $(0.05) per diluted ...